This panel explored how artificial intelligence is transforming drug discovery and development, from accelerating target identification to optimizing clinical trial design. Industry leaders and innovators will discuss how AI-driven insights are reshaping the future of precision medicine, speed, and success in bringing new therapies to patients.
Moderator: David Bearss, Ph.D., Halia Therapeutics, President & Chief Executive Officer
Panelists: Hariprasad Vankayalapati, Ph.D., Biolexis Therapeutics, Inc., Chief Scientific Officer; Ian Quigley, Ph.D., Leash Biosciences, CEO / Cofounder; Alison O’Mahony, Ph.D., Seek Labs, VP, Pharmaceutical Research
